The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT
Pau Abrisqueta, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, shares the findings from a Phase I/II trial investigating the use of subcutaneous epcoritamab and R-DHAX/C in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (autoSCT). Dr Abrisqueta explains that the safety profile of this combination was manageable, did not impair the feasibility of subsequent transplant, and compared favorably to chemoimmunotherapy (CIT) alone, including in patients with high-risk features. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie, Genmab, Roche, AstraZeneca, Beigene, BMS, Janssen: Consultancy, Speakers Bureau
